**Core Concept**
The management of chloroquine-resistant Plasmodium vivax malaria requires alternative antimalarial drugs that effectively target the parasite's life cycle. This involves understanding the pharmacological properties of various antimalarial agents and their mechanisms of action.

**Why the Correct Answer is Right**
Chloroquine-resistant P. vivax malaria is often treated with a combination of antimalarial drugs, such as primaquine and clindamycin. Primaquine acts by interfering with the parasite's heme detoxification pathway, while clindamycin targets the parasite's protein synthesis. These drugs can be used in combination to effectively manage chloroquine-resistant P. vivax malaria.

**Why Each Wrong Option is Incorrect**
**Option A:** Primaquine is actually used in the treatment of chloroquine-resistant P. vivax malaria, making it an incorrect choice. It is often used in combination with other antimalarial drugs, such as clindamycin.
**Option B:** Clindamycin is a suitable alternative for the treatment of chloroquine-resistant P. vivax malaria, often used in combination with primaquine. It is not the correct answer.
**Option C:** Artemisinin-based combination therapies (ACTs) are commonly used to treat chloroquine-resistant P. vivax malaria. They are not the answer we are looking for, but they are a correct option for treating P. vivax malaria.
**Option D:** Artemisinin itself is not typically used to treat P. vivax malaria, due to the risk of inducing resistance. However, the correct option is not listed, and this option is not the best choice.

**Clinical Pearl / High-Yield Fact**
When treating chloroquine-resistant P. vivax malaria, it is essential to use a combination of antimalarial drugs, such as primaquine and clindamycin, to effectively target the parasite's life cycle and prevent resistance.

**Correct Answer: D.